Body iron status and gastric cancer risk in the EURGAST study

• Main Authors: Fonseca-Nunes, A., Agudo, A., Aranda, N., Arija, V., Cross, A.J., Molina, E., Jose Sanchez, M., Bueno-de-Mesquita, H.B, Siersema, P., Weiderpass, E., Krogh, V., Mattiello, A., Tumino, R., Saieva, C., Naccarati, A., Ohlsson, B., Sjoberg, K., Boutron-Ruault, M.C., Cadeau, C., Fagherazzi, G., Boeing, H., Steffen, A., Kuehn, T., Katzke, V., Tjonneland, A., Olsen, A., Khaw, K.T, Wareham, N., Key, T., Lu, Y., Riboli, E., Peeters, P.H., Gavrila, D., Dorronsoro, M., Ramon Quiros, J., Barricarte, A., Jenab, M., Zamora-Ros, R., Freisling, H., Trichopoulou, A., Lagiou, P., Bamia, C., Jakszyn, P.
• Format: Article
• Published: John Wiley & Sons 2015
• Subjects: RC Internal medicine; RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://eprints.um.edu.my/16187/

Although it appears biologically plausible for iron to be associated with gastric carcinogenesis, the evidence is insufficient to lead to any conclusions. To further investigate the relationship between body iron status and gastric cancer risk, we conducted a nested case-control study in the multicentric European Prospective Investigation into Cancer and Nutrition (EPIC) study. The study included 456 primary incident gastric adenocarcinoma cases and 900 matched controls that occurred during an average of 11 years of follow-up. We measured prediagnostic serum iron, ferritin, transferrin and C-reactive protein, and further estimated total iron-binding capacity (TIBC) and transferrin saturation (TS). Odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of gastric cancer by iron metrics were estimated from multivariable conditional logistic regression models. After adjusting for relevant confounders, we observed a statistically significant inverse association between gastric cancer and ferritin and TS indices (ORlog2=0.80, 95% CI=0.72-0.88; OR10%increment=0.87, 95% CI=0.78-0.97, respectively). These associations appear to be restricted to noncardia gastric cancer (ferritin showed a p for heterogeneity=0.04 and TS had a p for heterogeneity=0.02), and no differences were found by histological type. TIBC increased risk of overall gastric cancer (OR50 mu g/dl=1.13, 95% CI=1.02-1.2) and also with noncardia gastric cancer (p for heterogeneity=0.04). Additional analysis suggests that time between blood draw and gastric cancer diagnosis could modify these findings. In conclusion, our results showed a decreased risk of gastric cancer related to higher body iron stores as measured by serum iron and ferritin. Further investigation is needed to clarify the role of iron in gastric carcinogenesis. What's new? Iron is highly reactive, iron levels in the body rise with inflammation, and the iron-overload disorder hemochromatosis is associated with an increased risk of gastric cancer. Thus, one might predict that high levels of iron will increase the risk of cancer. However, in this study from a large European population, the authors found that increased body iron stores actually decreased the risk of gastric cancer. These results suggest that further investigation is needed to clarify the role of iron in gastric carcinogenesis.